UNIQURE NV
QURENASDAQTrading Snapshot
- Day Range
- $23.58 – $23.83
- 52-Week Range
- $8.73 – $71.50
- Volume
- $2.42B
- Avg Volume
- $2.80B
- Shares Outstanding
- 69.4M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $5M
- P/E Ratio
- —
- P/S Ratio
- 142.0x
- EPS (TTM)
- $-4.05
- Dividend Yield
- —
- Dilution (1yr)
- +17.7%
Why Investors Own QURE
- ✓High-growth profile — revenue up -4.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
UNIQURE NV
QURE
StockOtter · stockotter.spaceAbout UNIQURE NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
UNIQURE NV tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift QURE price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
UNIQURE NV announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.